Behavioral Economics Incentives to Support HIV Treatment Adherence (BEST) in Uganda

How to cite

Linnemayr, Sebastian. 2019. "Behavioral Economics Incentives to Support HIV Treatment Adherence (BEST) in Uganda." AEA RCT Registry. AEARCTR-0003791. https://doi.org/10.1257/rct.3791-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Sebastian Linnemayr*

* Primary investigator

Registry ID
AEARCTR-0003791
DOI
https://doi.org/10.1257/rct.3791-1.0
First registered
Last updated
Status
On going
Trial dates
2018-04-12 – 2023-03-01
Countries
Private
JEL codes
I12, I15, I31, J13, D91, C93
Secondary IDs
NCT03494777
Registry record
http://www.socialscienceregistry.org/trials/3791

Abstract

Background: Many HIV-positive patients do not adhere to their antiretroviral medication (ART). This leads to higher viral loads and greater probability of transmission. Present bias—a tendency to give in to short-term temptations at the expense of long-term outcomes—is a potential driver of low adherence. In this study we test a novel intervention rooted in behavioral economics that is designed to overcome present bias and increase ART adherence.

Methods/Design: We will enroll 400 HIV-positive patients (330 core sample, and 70 additional as described below) at Mildmay hospital in Kampala, Uganda in a two-year randomized controlled trial. Participants will be randomized to one of three groups. The first intervention group (T1, n=110) will be eligible for small lottery prizes based on timely clinic visits and demonstration of viral suppression. Group 2 (T2, n=110) will be eligible for the same lottery prizes conditional on high electronically measured adherence as captured by a medication event management system (MEMS)-cap. The control group (n=110) will receive the usual standard of care. In addition, 70 treatment initiators (those who started treatment within the last three months) will also be recruited and assigned to T2. Adherence will be measured continuously throughout the study and for 12 months post-intervention to evaluate effect persistence, surveys will be conducted at baseline and then every six months, and viral loads will be measured annually. Primary outcomes are undetectable viral load and MEMS-measured adherence. Secondary outcomes are log transformed viral load as a continuous measure and a binary measure for whether the person adhered to greater than 90 percent of their ART pills.

Discussion: Our study is one of the first to investigate the effectiveness of lottery incentives for improving ART adherence, and in addition compares the relative efficacy of using measured adherence versus timely clinic visits and suppressed viral load to determine lottery eligibility. MEMS-caps are relatively costly, whereas viral load testing is now part of routine clinical care in Uganda. BEST will test whether directly incentivizing timely clinic visits and viral suppression (which canbe implemented using readily available clinic data) is as effective as incentivizing electronically measured adherence. Cost-effectiveness analyses of the two implementation modes will also be performed.

Intervention

There will be two intervention arms, both of which will use lottery-based incentives. In Treatment Group 1 (T1), clients will be eligible for quarter-yearly lotteries with small prizes based on timely drug refills and annual large prize lotteries if they demonstrate viral suppression. In Treatment Group 2 (T2), clients will be eligibility for quarterly small prize lotteries and annual larger prize lotteries based on high adherence as measured by electronic devices known as medication event management systems (or MEMS-caps). The control group will receive care as usual, including any adherence support mechanisms that are present within usual care practices. All participants including those in the control group will receive MEMS-caps.

Experimental design

This study will use a three-armed randomized controlled trial (two intervention groups and one control group), with 1:1:1 randomization at the individual level. The intervention will last for 24 months. The study will be conducted at Mildmay Uganda, an NGO with headquarters in Uganda’s capitals Kampala. Mildmay Uganda specializes in the provision of comprehensive HIV and AIDS prevention, care, and treatment services.

Design details

Randomization method
Random treatment assignment will occur after participants are recruited, but before they complete a baseline survey using a 1:1:1 ratio. We will stratify random assignment on age (under-25 or over-25 years of age), gender, marital status (married/cohabiting or unmarried), low CD4 count (below 200 or above 200), and viral load (detectable or undetectable). Stratified randomization is achieved by generating a separate block for each combination of covariates identifying which clients fall into each block. We will then randomize treatment assignment within each block. We will use the randtreat package in Stata15 to carry out the randomization procedure.
Randomization unit
Client-level (i.e. individual)
Clusters
330 treatment-mature clients and 70 treatment-initiating clients
Observations
330 treatment-mature clients and 70 treatment-initiating clients
Arms
110 clients per arm, plus 70 treatment initiators in the T2 arm eligible for prize drawings conditional on high MEMS-cap measured adherence
Primary outcomes
We will have one biological primary outcome and one behavioral primary outcome, namely viral suppression, and the percent of prescribed medication taken (mean adherence), respectively.
Secondary outcomes
Viral Load as continuous variable, and measure of adherence (90%)

Cited by

No citation data available for this registration yet.

Keywords